Drugs / Galibone+
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06338241 | Mar 2024 → Jun 2025 | bone resorption disease | Mario Pérez Sayáns | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Galibone+ | “The clinical study aims to assess the osteogenic effects of Galibone+ in bone regeneration post-extraction of impacted mandibular third molars.” NCT06338241 ↗ |
| Route | Other | “Applied post-extraction into the socket using specialized instruments” NCT06338241 ↗ |